TYMS underexpression
|
CRC
|
TYMS underexpression
|
CRC
|
bevacizumab Sensitive: C3 – Early Trials
|
bevacizumab Sensitive: C3 – Early Trials
|
TYMS underexpression
|
CRC
|
TYMS underexpression
|
CRC
|
arfolitixorin Sensitive: C3 – Early Trials
|
arfolitixorin Sensitive: C3 – Early Trials
|
TYMS underexpression
|
CRC
|
TYMS underexpression
|
CRC
|
FOLFIRI Sensitive: C3 – Early Trials
|
FOLFIRI Sensitive: C3 – Early Trials
|
TYMS underexpression
|
CRC
|
TYMS underexpression
|
CRC
|
FOLFOX Sensitive: C3 – Early Trials
|
FOLFOX Sensitive: C3 – Early Trials
|
TYMS underexpression
|
Soft Tissue Sarcoma
|
TYMS underexpression
|
Soft Tissue Sarcoma
|
cisplatin + pemetrexed Sensitive: C3 – Early Trials
|
cisplatin + pemetrexed Sensitive: C3 – Early Trials
|